anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and produced a worldwide pandemic in 2020. There have been 770,875,433 confirmed cases and 6,959,316 attributed deaths worldwide until September 19, 2023. The virus can also affect the lower urinary tract (LUT) leading to bladder inflammation and producing lower urinary tract symptoms (LUTS) in both the acute and chronic phases of disease.
METHODS: At the 2023 meeting of the International Consultation on Incontinence-Research Society (ICI-RS), the literature relating to COVID-19 and bladder dysfunction was reviewed. The LUTS reported, as well as the pathophysiology of these bladder symptoms, were the subject of considerable discussion. A number of different topics were discussed including lower LUTS reported in COVID-19, how SARS-CoV-2 may infect and affect the urinary tract, and proposed mechanisms for how viral infection result in new, worsened, and in some persisting LUTS.
CONCLUSIONS: The workshop discussed the interaction between the virus and the immune system, covering current evidence supporting theories underlying the causes of acute and chronic LUTS related to COVID-19 infection. Research questions for further investigation were suggested and identified.
PURPOSE:To obtain a drug effective for treating dermatosis of the human body, by smoking rice bran with charcoal fire, etc., to afford an extracted liquid. CONSTITUTION:A sheet of tough Japanese paper 6 is tied with a string to cover a vessel 4 and fresh rice bran 2 is placed thereon. Charocal fire 1 is then placed on the paper 6 to start smoking of the rice bran 2. When the whole temperature is reduced after the lapse of several hr or more, an extract 5, together with a black semisolid carbonized material, is precipitated. The resultant precipitated liquid is used as an active ingredient to provide a remedy for scall, ring worm, alopecia areata, initial white spot disease, etc., without particular side effect. If the drug is applied to an affected part by a finger, etc., the itching is stopped within about 1 week - 10 days. EFFECT:The material for the rice bran oil is readily purchased and the production is readily carried out.
BACKGROUND: While endovascular aneurysm repair has become a first-line strategy in many centers, open surgical repair (OSR) of abdominal aortic aneurysms (AAAs) is still the best option for certain patients. A significant number of patients who are offered OSR for AAA have been previously submitted to other open abdominal surgeries (PAS). It is unclear, however, how this may impact their outcomes. The purpose of this study was to determine if there is an association between PAS and outcomes of OSR of AAA.
METHODS: This is a retrospective cohort study based on clinical data from the American College of Surgeons National Surgical Quality Improvement Program database, including all patients undergoing elective OSR for AAA between 2011 and 2017. Excluded were patients with missing data on prior abdominal surgery, supramesenteric clamping, or urgent repairs. Patients with prior abdominal surgery (PAS) and patients without prior abdominal surgeries (nonPAS) were compared. The primary outcome was 30-day postoperative mortality. Secondary outcomes were operating time, ischemic colitis, postoperative complications, and lengths of hospital stay.
RESULTS: Of the 2034 patients included, 27% had previous open abdominal surgery and 73% did not. Overall, the median age was 71(interquartile range 65-76), 72% of patients were male, 44% were smokers, and the average body mass index was 27 kg/m2. Univariate analysis showed no difference in postoperative 30-day mortality (4.0% PAS vs. 4.1% nonPAS, P = 0.91) or overall postoperative complication rates (33% PAS vs. 29% nonPAS, P = 0.07). Previous open abdominal surgery was significantly associated with longer operating times (P = 0.032) and an almost doubled rate of ischemic colitis (4.7% PAS vs. 2.6% nonPAS, P = 0.02). Postoperative intensive care unit and hospitalization were also significantly longer in patients with prior abdominal surgery (P = 0.005 and P = 0.014, respectively). Finally, there were significantly less patients discharged home, as opposed to institutionalized care (75.7% PAS down from 82.4% nonPAS, P = 0.001). Despite these initial univariate analysis results, on multivariate analysis, PAS actually did not prove to be a statistically significant independent risk factor for 30-day mortality, ischemic colitis, or longer operating times.
CONCLUSIONS: This study suggests that patients who have undergone PAS may have some disadvantages in OSR of AAA. However, these negative trends do not go so far as to statistically significantly identify PAS as an independent risk factor for 30-day mortality, ischemic colitis, or longer operating times. As such, we suggest that a history of previous open abdominal surgery, in and of its own, should not exclude patients from consideration for open aortic abdominal aneurysm repair.
Female patients (aged 18-65) with FBD (irritable bowel syndrome, painful constipation and/or functional abdominal pain) will be enrolled at UNC-Chapel Hill and Toronto, Canada. A severity index will determine recruitment into the group of moderate FBD (200 patients) and severe FBD (100 patients). Each group will be randomized into the three treatment arms (cognitive-behavioral treatment, desipramine, and education/attention placebo), treated over a 12-week period, and followed for one year. Outcome measures will include symptoms (standardized abdominal pain, stool form and frequency) using diary cards, daily functional status (Sickness Impact Profile), depression (HAM-D) and psychological distress (SCL-90), physiological measures (enhanced rectal motility and visceral sensation), and health care use. Multivariate statistical methods with a hierarchical design will be applied to the data to assure maintenance of statistical power over multiple tests of overlapping groups.

The results of this study should significantly improve our understanding of this complicated syndrome that lowers the quality of life and economic productivity of large numbers of women. The clinical impact of the study, in providing physicians with scientific evidence of the efficacy of treatments of FBD that are commonly used in practice, is significant. We anticipate that this study will provide clinicians with predictors of success among types of FBD patients and types of therapy that will improve symptoms and quality of life, and reduce the health care costs associated with this common syndrome while improving patient-physician satisfaction.
PURPOSE: Daily postoperative anal dilations after endorectal pull-through for Hirschsprung disease (HD) are still considered a common practice. We analyzed the potential risks of this procedure and its effectiveness compared to a new internal protocol.
METHODS: All infants (< 6 months of age) who underwent transanal endorectal pull-through between January 2021 and January 2023 were prospectively enrolled in a new postoperative protocol group without daily anal dilations (Group A) and compared (1:2 fashion) to those previously treated by postoperative anal dilations (Group B). Patients were matched for age and affected colonic tract. Patients with associated syndromes, extended total intestinal aganglionosis, and presence of enterostomy were excluded. Outcomes considered were: anastomotic complications (stenosis, disruption/leakage), incidence of enterocolitis, and constipation.
RESULTS: Eleven patients were included in group A and compared to 22 matched patients (group B). There were no significant differences in the occurrence of anastomotic complications between the two groups. We found a lower incidence of enterocolitis and constipation among group A (p = 0.03 and p = 0.02, respectively).
CONCLUSION: A non-dilation strategy after endorectal pull-through could be a feasible alternative and does not significantly increase the risk of postoperative anastomotic complications. Moreover, some preliminary advantages such as lower enterocolitis rate and constipation should be further investigated.
The invention discloses a formula composition and a preparation method of a compound clove mouthwash. Comprises the following steps: the formula comprises the following components: 2-10 parts of clove, 2-10 parts of mint, 2-10 parts of wrinkled giant hyssop, 0-5 parts of jasmine flower and 0-5 parts of liquorice. The preparation method comprises the following steps: adding 10-30 times of water into the clove, heating and extracting volatile oil for 2-10 hours, and collecting volatile oil distillate and water decoction. Adding 10-30 times of water into herba Menthae, herba Agastaches and flos et flos Hibisci, heating to extract volatile oil, collecting volatile oil distillate and water decoction for 1-6 hr. Adding 4-20 times of water into licorice, heating and decocting for 2 times, the first time is 1-4 hours, the second time is 1-3 hours, and combining the extracting solutions. Mixing the volatile oil extract and the water decoction uniformly. The gargle is characterized by being prepared from clove, peppermint, wrinkled giant hyssop, jasmine and liquorice, is used for eliminating halitosis, cleaning and nursing oral cavity, and is suitable for all people by spraying or gargling.
A system for publicly displaying messages includes one or more mobile units, each including an automotive vehicle carrying a publicly visible electronic display; a computer for controlling the images shown on the display; and a radio for transmitting and receiving information, including information about which messages should be shown on the mobile unit's display. A central system receives and sends information to radios on the mobile units to control what messages they display. In some embodiments the mobile unit includes programming to enable a remote computer, such as a central system computer, to have remote access over the radio to commands of the mobile unit's computer's operating system. In some embodiments, the information transmitted by a mobile unit's radio includes information about the status of the mobile unit's computer. This can include how much more room its memory has, how utilized its CPU is, how much radio traffic it is having, what display message it is currently showing, etc. In some embodiments, the radio transmits real time information about the status of the mobile display unit. This can include information about one or more temperatures in the display device, the amount of light falling on or near the display's screens, the amount of light emitted by the display's screens, whether or not the vehicle's ignition is on, and the strength of the signal being received by a mobile unit's radio.
The invention discloses eucommia ulmoides fine powder and a preparation method thereof. The eucommia ulmoides fine powder comprises the following components: larger than or equal to 15 percent of total sugar, larger than or equal to 5 percent of chlorogenic acid, larger than or equal to 15 percent of total flavone, larger than or equal to 1.8 percent of geniposidic acid, larger than or equal to 0.8 percent of aucubin, less than or equal to 6.0 percent of water and trace elements such as B, Ca, Cu, Mg, Mn, P, Se, Zn, Na, K and Fe. According to the preparation method, the eucommia ulmoides fine powder is efficiently extracted from eucommia ulmoides leaves and eucommia ulmoides bark and a membrane technology is introduced for separation, concentration, decoloration and the like, so that the labor and time are reduced, the product quality and yield can also be improved, the temperature of the extraction process is low, and the damage of high temperature heating on effective components is avoided. In addition, the phenomenon that the eucommia ulmoides fine powder is insoluble in water the second time is avoided. The eucommia ulmoides fine powder belongs to a natural health food preparation, is safe and non-toxic, and is suitable for the industries such as medicine, health care products and food antioxidants. Eucommia ulmoides gum can be continuously extracted out from extractive residue after extraction of the eucommia ulmoides fine powder, and the economic benefit of high-value using of eucommia ulmoides is effectively improved.
Participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
Subjects will receive Fentanyl for analgesia and midazolam for sedation management. The RASS score is used to guide sedation to a goal of 0 to -2 and daily sedation by IV Midazolam at 1 mg/hr and titrated by 1 mg/hr q60 mins. Midazolam boluses are allowed by 1 mg IVP q5 mins x2 before increasing the infusion rate. Propofol and dexmedetomidine are permitted under existing institutional sedation protocol. Fentanyl IV starts at 50 mcg/hr and is titrated by 25 mcg/hr q15 mins to achieve target pain score. Fentanyl bolus of 25 mcg IVP q5 min x2 doses is given before increasing the infusion rate. Daily sedation interruption (DSI) is performed daily and ventilator weaning trial if they pass.
PURPOSE: To provide hexagonal BN-fluorinated graphite combined powder excellent in lubricity, water repellency, etc., and suitable for use as stock of cosmetics, etc., by using hexagonal BN as mother particles and fluorinated graphite as child particles and combining them. CONSTITUTION: Hexagonal BN is used as mother particles, fluorinated graphite is used as child particles and they are combined to obtain the objective hexagonal BN-fluorinated graphite combined powder. The average particle diameter of the fluorinated graphite is preferably <=1/5 of that of the hexagonal BN and the average particle diameter of the hexagonal BN is preferably 0.5-30μm. The fluorinated graphite powder is generally used by about 1-20 pts.wt. per 100 pts.wt. of the hexagonal BN powder at the time of combining treatment and this treatment is preferably carried out using a high-speed eliptical rotor type mixing device because the powders can be most uniformly combined.
Participants receive three monthly Eylea treatments (Day 1, Month 1, and Month 2) followed by Zimura administered on the same day. All participants will receive treatment every 3 months for a total of 18 months. If there is a loss of visual acuity during the intervening visits, participants may be retreated with Eylea and Zimura.
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a respiratory disorder with a complex etiology involving genetic and environmental factors. The dysbiosis of gut microbiota has been implicated in COPD. Mendelian Randomization (MR) provides a tool to investigate causal links using genetic variants as instrumental variables. This study aims to employ MR analysis to explore the causal relationship between gut microbiota, lung function, and COPD.
METHODS: We utilized genome-wide association study (GWAS) data from MiBioGen, UK Biobank and FinnGen, which were related to gut microbial taxa, lung function parameters including forced vital capacity in one second (FEV1), forced vital capacity (FVC), and percentage of predicted FEV1 (FEV1%pred), as well as GWAS data for COPD. MR analysis was conducted to assess the causal effects of gut microbiota on lung function and the risk of COPD. Sensitivity analysis was utilized to examine the stability of the causal relationships. Multiple testing and reverse analysis were employed to evaluate the robustness of these relationships.
RESULTS: Using the IVW method, 64 causal correlations were identified. Through conducting sensitivity analysis, multiple testing, and reverse analysis, we identified 14 robust and stable causal relationships. The bacterial taxa that showed a positive association with lung function included Desulfovibrionaceae, Erysipelotrichales, Desulfovibrionales, Clostridiales, Clostridia, Deltaproteobacteria and Erysipelotrichia, while Selenomonadales and Negativicutes showed a negative association with lung function. The abundance of Holdemanella were positively correlated with the risk of COPD, while FamilyXIII exhibited a negative correlation with the risk of COPD.
CONCLUSION: Several microbial taxa were discovered to have a positive causal correlation with lung function, offering potential insights into the development of probiotics. The presence of microbial taxa negatively correlated with lung function and positively correlated with COPD emphasized the potential impact of gut microbiota dysbiosis on respiratory health.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use excellent in skin beautifying and whitening effects and preventing and improving effects on skin roughening by including an ester derivative (salt) of ornithine. SOLUTION: This skin preparation for external use is obtained by including (A) 0.001-20 wt.%, preferably 0.01-7 wt.% of an ester derivative (salt) of ornithine represented by the formula (R is an alkyl, an aralkyl or an alkenyl) and, as necessary, (B) an oil, an ultraviolet absorber, an antioxidant, a surfactant, a humectant, a perfume, water, an alcohol, a thickener, a colorant, a skin nutrient preparation (e.g. tocopherol acetate) or the like. The ingredient A may be any of the L-, D- and DL-isomers. The ingredient A is obtained by reacting, e.g. ornithine with an alcohol in the presence of an acidic catalyst.  Inorganic acid salts such as that of hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid or organic acid salts such as that of acetic acid, lactic acid, maleic acid, fumaric acid, tartaric acid, citric acid, methanesulfonic acid or p- toluenesulfonic acid are cited as the salt of the ingredient A.
Prostate cancer is the most frequently diagnosed cancer in men and the second leading cause of cancer-related death in men in the United States. Chemotherapy, either as a single agent or in combination, may lead to clinical response, pain control, and/or improved quality of life. Docetaxel is now the first-line standard therapy for AIPC. Mitoxantrone was approved in 1996 for use in combination with corticosteroids as initial chemotherapy for pain related to advanced Hormone Refractory Prostate Cancer (HRPC). Hormonal manipulations and docetaxel-based chemotherapy are often effective in metastatic prostate cancer; however, disease becomes refractory to these interventions in the majority of men. Although mitoxantrone continues to be a significant agent in the treatment of HRPC, there exists a need for more efficacious therapy in docetaxel-refractory- AIPC. Because of the potential contribution of Insulin Like Growth Factor Receptor (IGF-IR) and VEGFR-2 mediated pathways in prostate cancer pathogenesis, it is hypothesized that each of these biological agents in combination with mitoxantrone and prednisone will result in clinically meaningful activity in AIPC. Therefore, ImClone plans to conduct a randomized Phase 2 trial to assess the safety and efficacy of IMC-A12 or IMC-1121B (ramucirumab) in combination with mitoxantrone and prednisone in participants with AIPC.
Cirrhosis is the final pathway of chronic liver disease, and up to 30% of patients develop hepatocellular carcinoma (HCC) within 5 years of diagnosis of cirrhosis. Worldwide, chronic hepatitis C (CHC) and B (CHB) account for the majority of cases of cirrhosis. Successful antiviral treatment results in regression of fibrosis in the majority of patients. Surveillance programs for early detection of HCC mandate the use of imaging (ultrasound/CT-scan) every 6 months. It has been shown in CHC and CHB that the risk of HCC is greatly reduced after viral disease is eradicated/inactive. However, the impact that regression of fibrosis and other factors could have in abating the incidence of HCC has not been systematically investigated. Currently, all patients with eradicated/inactive viral disease continue to be enrolled in HCC surveillance programs, generating anxiety in patients and very high costs to our healthcare system. Fibrotest (FT) and transient elastography (TE) are noninvasive tools proven to be useful for serial assessment of liver fibrosis.

OBJECTIVES: The proposed hypothesis is that patients with regression of liver fibrosis have decreased risk for HCC. Primary aim is to determine the incidence of HCC in patients with cirrhosis secondary to CHC and CHB, during the 3-7 years after treatment is provided, and to identify the magnitude of the decreased risk for HCC in patients experiencing regression of fibrosis. As a secondary aim, environmental risk factors for HCC development will be sought, in order to determine a subset of patients in whom it will be safe to stop surveillance.

METHODS: Patients 18-70 year-old with cirrhosis will be identified from hepatology clinics in 4 academic centers in North America. FT/TE will be obtained before the start of antivirals and yearly thereafter (prospective arm). A retrolective arm of all patients treated no earlier than Jan/2009 will also be included. In this group, baseline FT/TE will be performed off treatment (CHC) or after initial phase of therapy (CHB), and yearly thereafter. During baseline and yearly visits other factors possibly affecting HCC development will be investigated (family history, comorbidities, BMI, diet, etc.). Patients will be classified as having or having not undergone regression of fibrosis after a 3-year follow up, depending on FT and TE evolution. During follow up, all patients will undergo 6-month imaging as part of their routine HCC surveillance. Based on power calculations, enrollment should stop after 924 patients have been recruited. Kaplan-Meier and Cox regression models will be used to analyze data.

PATIENT OUTCOMES: ROLFH study uses state-of-the-art noninvasive markers of liver fibrosis to test whether reversed fibrosis decreases the risk of HCC. We believe this study will lead to a better understanding of HCC risk factors, improved patient counseling and decision making, optimized screening and allocation of health resources, and decreased healthcare costs.
Accuracy of implant positioning and reconstruction of the mechanical leg axis are major requirements for achieving good long-term results in total knee arthroplasty (TKA). A minimally invasive approach might compromise the accuracy due to lacking intraoperative oversight. The purpose of this study is to compare a minimally invasive TKA approach that was performed under control of a navigation system with a standard navigated approach, with respect to patient pain and range of motion.

All patients receive a Columbus knee prosthesis and in both groups an OrthoPilot navigation system is used to control the alignment. Pain intensity using the Visual Analogue Scale (VAS) and concomitant pain medication intake are documented daily during the first 20 days after operation. As long as the patient is hospitalized the Range of Motion will also be documented daily. Knee society score, oxford score, as well as the WOMAC score are monitored pre- and postoperatively.